{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:07:31Z","timestamp":1774580851473,"version":"3.50.1"},"reference-count":27,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,14]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Heart failure (HF), chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD) are highly prevalent conditions that often coexist. Using electronic health records (EHRs), we evaluated the 1-year risk of all-cause death, major cardiovascular and kidney events in patients with HF, CKD, ASCVD and with combinations of these conditions, compared with an unselected control population aged \u226575 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study based on EHR data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Integrated primary and secondary health unit located in the North of Portugal. Eligible adult patients were identified using EHRs from 2008 to June 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Eight cohorts were defined: (1) control: patients with \u226575 years; (2) ASCVD alone; (3) HF alone; (4) CKD alone; (5) cardiorenal syndrome (CRS): combined HF+CKD; (6) atherosclerotic HF: combined ASCVD+HF without CKD; (7) atherosclerotic CKD: combined ASCVD+CKD without HF and (8) combined ASCVD+CRS. The risk of these conditions was compared with controls using propensity score age-sex matching. We identified 19 129 patients with ASCVD alone, 13 640 patients with HF alone, 40 545 with CKD alone and 10 499 with CRS. The control group comprised 36 532 patients aged 75 years or older.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The primary outcome was all-cause mortality. The main secondary outcomes were cardiovascular death, HF hospitalisations and end-stage renal disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 1-year mortality rate was 0.65% in the control cohort, 5.6% for patients with ASCVD alone, 6.05% for patients with HF alone and 3.53% for patients with CKD alone. Adjusted risk of all-cause death was significantly increased in the ASCVD-alone (HR: 8.42, 95%\u2009CI 7.12 to 9.95), HF-alone (HR: 9.19, 95%\u2009CI 7.75 to 10.9) and CKD-alone (HR: 5.35, 95%\u2009CI 4.62 to 6.19) cohorts, compared with control population; however, patients with the combination of all three conditions (ie, ASCVD+CRS) had the highest mortality risk (HR: 14.18, 95%\u2009CI 11.62 to 17.3). A similar association pattern was observed for cardiovascular death, HF events and end-stage renal disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results support the concept of an atherosclerotic cardiorenal phenotype, with a very high risk of mortality, cardiovascular and renal adverse events. Implementation strategies are required to target these conditions simultaneously.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-094853","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:40:36Z","timestamp":1763358036000},"page":"e094853","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic impact of heart failure, chronic kidney disease and atherosclerotic disease alone or combined in an elderly population: a retrospective cohort study based on electronic health record data"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"Centre d\u2019Investigation Clinique Plurith\u00e9matique de Nancy, Vand\u0153uvre-l\u00e8s-Nancy, Grand Est, France"}]},{"given":"Tiago","family":"Taveira-Gomes","sequence":"additional","affiliation":[{"name":"University of Porto Faculty of Medicine, Porto, Portugal"}]},{"given":"Rita","family":"Lopes","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Health Information and Decision, University of Porto, Porto, Portugal"}]},{"given":"Daniel","family":"Seabra-Carvalho","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Matosinhos, Matosinhos, Portugal"}]},{"given":"Filipa","family":"Bernardo","sequence":"additional","affiliation":[{"name":"Medical Department, AstraZeneca, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2553-8264","authenticated-orcid":false,"given":"Cristina","family":"Gavina","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculdade de Medicina da Universidade do Porto, Porto, Portugal"}]}],"member":"239","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"2025120413274825000_15.11.e094853.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2019.07.003"},{"key":"2025120413274825000_15.11.e094853.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000664"},{"key":"2025120413274825000_15.11.e094853.3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht386"},{"key":"2025120413274825000_15.11.e094853.4","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.066464"},{"key":"2025120413274825000_15.11.e094853.5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1055\/a-1508-3912","article-title":"Prevalence of Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Primary Care Research Network-based Study","volume":"130","author":"Goderis","year":"2022","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2025120413274825000_15.11.e094853.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab011"},{"key":"2025120413274825000_15.11.e094853.7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ejhf.600","article-title":"Reframing the association and significance of co-morbidities in heart failure","volume":"18","author":"Triposkiadis","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2025120413274825000_15.11.e094853.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2015.173"},{"key":"2025120413274825000_15.11.e094853.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01643-X"},{"key":"2025120413274825000_15.11.e094853.10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025120413274825000_15.11.e094853.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"2025120413274825000_15.11.e094853.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"2025120413274825000_15.11.e094853.13","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1236008","article-title":"Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat","volume":"10","author":"Geng","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2025120413274825000_15.11.e094853.14","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.18360"},{"key":"2025120413274825000_15.11.e094853.15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025120413274825000_15.11.e094853.16","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/ehf2.14531","article-title":"Missed opportunities in the diagnosis of heart failure: a real-world assessment","volume":"10","author":"Ferreira","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2025120413274825000_15.11.e094853.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2025120413274825000_15.11.e094853.18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009427","article-title":"Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort","volume":"15","author":"Welsh","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2025120413274825000_15.11.e094853.19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022833","article-title":"Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death","volume":"11","author":"Brady","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025120413274825000_15.11.e094853.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.05.017","article-title":"Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study","volume":"384","author":"Gavina","year":"2023","journal-title":"Atherosclerosis"},{"key":"2025120413274825000_15.11.e094853.21","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.cardfail.2025.04.016","article-title":"Screening for Undiagnosed Heart Failure: A Viewpoint","volume":"31","author":"Ferreira","year":"2025","journal-title":"J Card Fail"},{"key":"2025120413274825000_15.11.e094853.22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jchf.2024.10.025","article-title":"We Need Simpler and More Integrated Guidelines in Cardio-Kidney-Metabolic Diseases","volume":"13","author":"Ferreira","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2025120413274825000_15.11.e094853.23","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.37765\/ajmc.2024.89671","article-title":"Diabetes, cardiorenal, and metabolic multispecialty practice recommendations and early intensive management of cardio-renal-metabolic disease","volume":"30","author":"Handelsman","year":"2024","journal-title":"Am J Manag Care"},{"key":"2025120413274825000_15.11.e094853.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001184"},{"key":"2025120413274825000_15.11.e094853.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-018-1302-7"},{"key":"2025120413274825000_15.11.e094853.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-020-01170-w","article-title":"Body mass index and cardiovascular outcomes in patients with acute coronary syndrome by diabetes status: the obesity paradox in a Korean national cohort study","volume":"19","author":"Park","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2025120413274825000_15.11.e094853.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.068"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-094853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:29:48Z","timestamp":1764883788000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-094853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,16]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2024-094853"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-094853","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}